AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14752209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone replacement therapy
Number of subjects: 112
Study 14752209 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 112
Study 11490232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 168
Study 11490232 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 168
Study 11490232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor volume measurement
Number of subjects: 168
Study 9207222 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate
Number of subjects: 0
Study 8135108 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaprose S (30 mg tablets, 3 tab/day)
Number of subjects: 320
Study 8135108 — intervention group
Group type: COMPARATOR
Intervention: Nimesulide (100 mg, 2 tab/day)
Number of subjects: 320
Study 3309827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 581
Study 3309827 — intervention group
Group type: COMPARATOR
Intervention: Josamycin
Number of subjects: 581
Study 3309827 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V
Number of subjects: 581
Study 30932776 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (330 mg) and vitamin D3 (0.005 mg or 200 IU) per day
Number of subjects: 84
Study 30932776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 29439278 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 343
Study 29439278 — intervention group
Group type: EXPERIMENTAL
Intervention: M-NBI
Number of subjects: 343
Study 29439278 — intervention group
Group type: COMPARATOR
Intervention: Comparison of M-NBI and chromoendoscopy
Number of subjects: 343
Study 28009335 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 40
Study 28009335 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 40
Study 24332577 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+HealthCall
Number of subjects: 139
Study 24332577 — intervention group
Group type: COMPARATOR
Intervention: MI-only
Number of subjects: 139
Study 23516319 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 106
Study 23516319 — intervention group
Group type: COMPARATOR
Intervention: 10-Hz rTMS
Number of subjects: 106
Study 23516319 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 106
Study 23516319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmotor symptoms (all groups)
Number of subjects: 106
Study 20197486 — intervention group
Group type: EXPERIMENTAL
Intervention: laropiprant 40 mg for 10 days + single-dose digoxin 0.5 mg
Number of subjects: 13
Study 20197486 — intervention group
Group type: COMPARATOR
Intervention: single-dose digoxin 0.5 mg
Number of subjects: 13
Study 19022184 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 127
Study 19022184 — intervention group
Group type: COMPARATOR
Intervention: No PTA (control)
Number of subjects: 127
Study 16822131 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthographically related nonword primes
Number of subjects: 0
Study 16822131 — intervention group
Group type: COMPARATOR
Intervention: Orthographically related word primes
Number of subjects: 0
Study 16822131 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime and target sharing a neighbor
Number of subjects: 0
Study 16822131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-N nonword foils
Number of subjects: 0
Study 12814902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.4 g/kg, 22‐28 g) twice daily for 8 days
Number of subjects: 9
Study 12814902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (juice)
Number of subjects: 9
Study 11855255 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased outcome clinical pathways for SCIs
Number of subjects: 0
Study 8936546 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivicaine (0.25%) 2 mg.kg-1 before surgical incision, followed by caudal normal saline infused at the same volume after surgical incision.
Number of subjects: 10
Study 8936546 — intervention group
Group type: COMPARATOR
Intervention: Caudal saline before surgical incision followed by caudal bupivicaine (0.25%) infused 15 min after surgical incision.
Number of subjects: 10
Study 1448244 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of Camper fascia with absorbable suture
Number of subjects: 438
Study 1448244 — intervention group
Group type: COMPARATOR
Intervention: No closure of Camper fascia
Number of subjects: 438
Study 6387197 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate, 20 to 30 mg/day
Number of subjects: 107
Study 6387197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 31740871 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary thyroid cancer (group 1)
Number of subjects: 90
Study 30310273 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 1756
Study 30310273 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 1756
Study 30310273 — intervention group
Group type: COMPARATOR
Intervention: GP MDI 18 μg
Number of subjects: 1756
Study 30310273 — intervention group
Group type: COMPARATOR
Intervention: FF MDI 9.6 μg
Number of subjects: 1756
Study 25756231 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training (3 times per week for 6 weeks)
Number of subjects: 32
Study 25756231 — intervention group
Group type: COMPARATOR
Intervention: Control group (no slackline training)
Number of subjects: 32
Study 26882607 — intervention group
Group type: EXPERIMENTAL
Intervention: External use of Shengji Ointment (SO), exchange once every 24 h for 21 days
Number of subjects: 440
Study 26882607 — intervention group
Group type: COMPARATOR
Intervention: External use of Votalin, exchange once every 24 h for 21 days
Number of subjects: 440
Study 22652506 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Number of subjects: 31
Study 22652506 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day meso‐zeaxanthin (MZ), 10 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Number of subjects: 31
Study 22652506 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 mg/day meso‐zeaxanthin (MZ), 3 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Number of subjects: 31
Study 20919513 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 0
Study 20919513 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Number of subjects: 0
Study 18806063 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 40
Study 18806063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15704026 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 100
Study 12232543 — intervention group
Group type: EXPERIMENTAL
Intervention: tianeptine (37.5 mg)
Number of subjects: 212
Study 12232543 — intervention group
Group type: COMPARATOR
Intervention: sertraline (50 mg)
Number of subjects: 212
Study 10091827 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (group A)
Number of subjects: 75
Study 10091827 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 75
Study 7749833 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 24
Study 7749833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1979463 — intervention group
Group type: EXPERIMENTAL
Intervention: Moditen-depot
Number of subjects: 0
Study 1979463 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 0
Study 1979463 — intervention group
Group type: COMPARATOR
Intervention: Routine maintenance therapy
Number of subjects: 0
Study 6311785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 g) administered by iv rapid injection
Number of subjects: 12
Study 6311785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 g) administered by im injection
Number of subjects: 12
Study 6311785 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (1 g) administered one hour before ceftizoxime
Number of subjects: 12
Study 6311785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probenecid)
Number of subjects: 12
Study 31249252 — intervention group
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 10 μg/kg
Number of subjects: 90
Study 31249252 — intervention group
Group type: COMPARATOR
Intervention: dexmedetomidine 5 μg/kg
Number of subjects: 90
Study 31249252 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 30373659 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic osteochondroplasty with or without labral repair
Number of subjects: 220
Study 30373659 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic lavage of the hip joint
Number of subjects: 220
Study 26945402 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG (150-225 IU) and MPA (10 mg/d) administered simultaneously starting on cycle day 3
Number of subjects: 120
Study 26945402 — intervention group
Group type: COMPARATOR
Intervention: Short protocol (control)
Number of subjects: 120
Study 26945402 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG + MPA
Number of subjects: 120
Study 24284453 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Number of subjects: 16
Study 24284453 — intervention group
Group type: COMPARATOR
Intervention: Gait training without RAS (Control)
Number of subjects: 16
Study 23265030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84
Study 23265030 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 84
Study 23265030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 84
Study 21094811 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) therapy for 3 months
Number of subjects: 75
Study 21094811 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) therapy
Number of subjects: 75
Study 17995484 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat information about novel animals
Number of subjects: 26
Study 17995484 — intervention group
Group type: COMPARATOR
Intervention: Positive information about novel animals
Number of subjects: 26
Study 17995484 — intervention group
Group type: COMPARATOR
Intervention: No information about novel animals
Number of subjects: 26
Study 16985503 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0, 0.02-0.04 mg%, or 0.06-0.08 mg%)
Number of subjects: 23
Study 16985503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15625770 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus HRT
Number of subjects: 29
Study 15625770 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine alone
Number of subjects: 29
Study 11106138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 11106138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8772580 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6)
Number of subjects: 7
Study 8772580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8772580 — intervention group
Group type: EXPERIMENTAL
Intervention: AC137
Number of subjects: 7
Study 1344238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine 1.5 mg/kg
Number of subjects: 50
Study 1344238 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (N/S) 0.1 ml/kg (control group)
Number of subjects: 50
Study 6141161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 74
Study 6141161 — intervention group
Group type: COMPARATOR
Intervention: 1 mg lorazepam
Number of subjects: 74
Study 6141161 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg clorazepate
Number of subjects: 74
Study 6141161 — intervention group
Group type: COMPARATOR
Intervention: 15 mg clorazepate
Number of subjects: 74
Study 29464411 — intervention group
Group type: EXPERIMENTAL
Intervention: Active head impulse VOR adaptation training for 15 minutes
Number of subjects: 10
Study 29464411 — intervention group
Group type: COMPARATOR
Intervention: Passive head impulse VOR adaptation training for 15 minutes
Number of subjects: 10
Study 29464411 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VOR training during two single 60-min interval sessions
Number of subjects: 10
Study 29464411 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a de-adaptation stimulus
Number of subjects: 10
Study 28811748 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity (70% peak power) cycling exercise
Number of subjects: 20
Study 28811748 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 20
Study 28811748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 20
Study 28811748 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 20
Study 28811748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of perceived exertion
Number of subjects: 20
Study 28811748 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination of stress response pathways (α‐amylase vs cortisol)
Number of subjects: 20
Study 26278823 — intervention group
Group type: EXPERIMENTAL
Intervention: IVDU-MV
Number of subjects: 172
Study 26278823 — intervention group
Group type: COMPARATOR
Intervention: MV
Number of subjects: 172
Study 22957889 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI) with raw hen's egg emulsion for 6 months
Number of subjects: 20
Study 22957889 — intervention group
Group type: COMPARATOR
Intervention: Control group (egg-free diet for 6 months)
Number of subjects: 20
Study 21477315 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic preoperative instruction
Number of subjects: 120
Study 21477315 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study 18176828 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal sutured incision (Group 1, n=45)
Number of subjects: 90
Study 18176828 — intervention group
Group type: COMPARATOR
Intervention: Open left incision (Group 2, n=45)
Number of subjects: 90
Study 16899964 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model with training for GPs and psychiatric consultation
Number of subjects: 81
Study 16899964 — intervention group
Group type: COMPARATOR
Intervention: Care as usual by the GP
Number of subjects: 81
Study 12928692 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg twice daily (b.i.d.)
Number of subjects: 35
Study 12928692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10822211 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day
Number of subjects: 44
Study 10822211 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 44
Study 8853772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid 500 mg and chenodeoxycholic acid 500 mg per day)
Number of subjects: 102
Study 8853772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 8853772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid and chenodeoxycholic acid)
Number of subjects: 102
Study 8853772 — intervention group
Group type: COMPARATOR
Intervention: Bile acids and Placebo
Number of subjects: 102
Study 1633897 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunization with husband's or third party leukocytes (44 patients)
Number of subjects: 89
Study 1633897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (27 patients)
Number of subjects: 89
Study 1633897 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy in pregnancy (18 patients)
Number of subjects: 89
Study 1633897 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined study groups (anticardiolipin antibody-positive vs. negative)
Number of subjects: 89
Study 6385838 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone (100 mg four times daily for 5 days)
Number of subjects: 94
Study 6385838 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (500 mg four times daily for 5 days)
Number of subjects: 94
Study 6385838 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 94
Study 6385838 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 94
Study 31929250 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 80
Study 31929250 — intervention group
Group type: COMPARATOR
Intervention: epsilon‐amino‐caproic acid
Number of subjects: 80
Study 31376274 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 intervention (5 sessions, 1 week apart)
Number of subjects: 117
Study 31376274 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 117
Study 28566122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation during the first days of life
Number of subjects: 12
Study 28566122 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition (control group)
Number of subjects: 12
Study 28566122 — intervention group
Group type: COMPARATOR
Intervention: Standardized weekly exchange of nasogastric feeding tubes
Number of subjects: 12
Study 26424102 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week health-promotion intervention
Number of subjects: 548
Study 24418693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/gemcitabine
Number of subjects: 0
Study 24418693 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 0
Study 24418693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 24418693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed
Number of subjects: 0
Study 23040713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral embolization after CAS for asymptomatic carotid stenosis
Number of subjects: 40
Study 23040713 — intervention group
Group type: COMPARATOR
Intervention: Cerebral embolization after CAS for symptomatic carotid stenosis
Number of subjects: 40
Study 23040713 — intervention group
Group type: EXPERIMENTAL
Intervention: New acute cerebral emboli detected with DW‐MRI in asymptomatic patients
Number of subjects: 40
Study 23040713 — intervention group
Group type: COMPARATOR
Intervention: New acute cerebral emboli detected with DW‐MRI in symptomatic patients
Number of subjects: 40
Study 23040713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral DW‐MRI lesions in asymptomatic patients
Number of subjects: 40
Study 23040713 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral DW‐MRI lesions in symptomatic patients
Number of subjects: 40
Study 23040713 — intervention group
Group type: EXPERIMENTAL
Intervention: Total DW‐MRI lesions in asymptomatic patients
Number of subjects: 40
Study 23040713 — intervention group
Group type: COMPARATOR
Intervention: Total DW‐MRI lesions in symptomatic patients
Number of subjects: 40
Study 23040713 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day stroke-death rate
Number of subjects: 40
Study 19132604 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-film processing with cognitive load during suppression
Number of subjects: 120
Study 19132604 — intervention group
Group type: COMPARATOR
Intervention: No-suppression control group
Number of subjects: 120
Study 19132604 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental groups
Number of subjects: 120
Study 18089377 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 mg/day)
Number of subjects: 0
Study 18089377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) (3 g/day)
Number of subjects: 0
Study 18089377 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 0
Study 18089377 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 18089377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study 15655272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 16
Study 15655272 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg
Number of subjects: 16
Study 11531666 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon sedation
Number of subjects: 0
Study 11531666 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 0
Study 15251771 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized glyburide (sulfonylurea)
Number of subjects: 18
Study 15251771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8350218 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (n = 25)
Number of subjects: 45
Study 8350218 — intervention group
Group type: COMPARATOR
Intervention: Whey-predominant formula (n = 20)
Number of subjects: 45
Study 3523550 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 3523550 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0
Study 29692287 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated analysis of disorganized speech using Coh-Metrix 3.0
Number of subjects: 81
Study 29692287 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated analysis of disorganized speech
Number of subjects: 81
Study 29692287 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined automated analysis and clinician-rated measures
Number of subjects: 81
Study 29255175 — intervention group
Group type: EXPERIMENTAL
Intervention: 0800 hours meal
Number of subjects: 20
Study 26621156 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/d lisdexamfetamine dimesylate (LDX)
Number of subjects: 0
Study 26621156 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg/d lisdexamfetamine dimesylate (LDX)
Number of subjects: 0
Study 26621156 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d lisdexamfetamine dimesylate (LDX)
Number of subjects: 0
Study 26621156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24449770 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperaquine with concomitant food
Number of subjects: 30